IRIDEX (NASDAQ:IRIX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management [Yahoo! Finance]
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
Iridex to Present at the Sidoti Year-End Virtual Investor Conference